CXR.TO - Concordia International Corp.

YHD - YHD Delayed Price. Currency in USD
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (3Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • Thomson Reuters StreetEvents

    Edited Transcript of CXR.TO earnings conference call or presentation 14-Nov-18 1:30pm GMT

    Q3 2018 Concordia International Corp Earnings Call

  • PR Newswire

    Concordia International Corp. Announces Name Change to ADVANZ PHARMA Corp.

    It is expected that the limited voting shares of the Company will begin trading under the new name, and that the Company's stock symbol will change from CXR to ADVZ, on or about December 3, 2018. "This is an exciting period for ADVANZ PHARMA, our stakeholders, and all our employees across the globe," said Graeme Duncan, the Company's Chief Executive Officer. "This new corporate identity, and the accompanying rebranding that we are working on, will help define ADVANZ PHARMA as a global pharmaceutical company that is determined to help innovate, shape and grow the specialty, off-patent sector.

  • CNW Group

    Concordia International Corp. Announces Third Quarter 2018 Results

    MISSISSAUGA, ON , Nov. 14, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (CXR.TO), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced its financial and operational results for the three and nine months ended September 30, 2018 . "Our third quarter results are consistent with our expectations," said Graeme Duncan , Chief Executive Officer of Concordia.

  • Analysts Estimate Concordia Healthcare (CXRXF) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Concordia Healthcare (CXRXF) to Report a Decline in Earnings: What to Look Out for

    Concordia Healthcare (CXRXF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • CNW Group

    Concordia International Corp. Announces Release Date for Third Quarter 2018 Results

    MISSISSAUGA, ON , Oct. 31, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (CXR.TO), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced it intends to release its third quarter 2018 financial results before market open on Wednesday, November 14, 2018 .

  • CNW Group

    Concordia International Corp. Adds European Pharmaceutical Industry Expert to its Board of Directors

    "We believe that Maurice's extensive experience in the European pharmaceutical market will support Concordia's focus to acquire targeted products and companies in our core and proximate markets, and expand our product portfolio," said Graeme Duncan , Chief Executive Officer of Concordia. Mr. Chagnaud has more than 25 years of experience in the pharmaceutical sector including senior and leadership roles at Merck KgAa, Merck Generics, Teva, Lupin and Polpharma. Concordia is an international specialty pharmaceutical company with a diversified portfolio of more than 200 patented and off-patent products, and sales in more than 90 countries.

  • CNW Group

    Concordia International Corp. Announces Addition of Pharmaceutical Industry Expert to its Board of Directors

    MISSISSAUGA, ON , Oct. 15, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (CXR.TO), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that it has appointed pharmaceutical industry expert Frances Cloud to its board of directors. "We are delighted to welcome Frances and believe that she will provide crucial experience to our board and Company," said Graeme Duncan , Chief Executive Officer of Concordia. Ms. Cloud has more than 20 years of experience in the pharmaceutical sector, including her time working as an analyst and investment banker for a number of banks, including Nomura International, IMI Securities and Swiss Bank Corporation (now part of UBS).

  • CNW Group

    Concordia International Corp. Announces Intention To Rebrand As ADVANZ PHARMA Following Its Successful Recapitalization

    MISSISSAUGA, ON , Oct. 9, 2018  /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (CXR.TO), announced today its intention to change its name as part of a global rebrand in support of its strategy and vision. ADVANZ PHARMA (Concordia International Corp.), will re-focus on delivering sustainable value across its portfolio of specialty generic and legacy branded, off patent medicines.

  • CNW Group

    Concordia International Corp. Announces Special Meeting of Shareholders To Approve Name Change

    MISSISSAUGA, ON , Oct. 5, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (CXR.TO), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today issued a notice of meeting (the "Meeting") of shareholders to consider and approve a name change (the "Name Change") of the Company. The Name Change is subject to approval by Limited Voting Shareholders ("Shareholders") at the Meeting. At least 66 2/3% of the votes cast by Shareholders present in person or represented by proxy at the Meeting is required to effect the Name Change.

  • CNW Group

    IIROC Trade Resumption - CXR

    IIROC Trade Resumption - CXR

  • PR Newswire

    Concordia International Corp. Provides Further Update On Its Recently Completed Recapitalization Transaction and the Issue Price of its Private Placement

    MISSISSAUGA, ON , Sept. 12, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR) issued a further announcement today, at the request of the Investment ...

  • CNW Group

    IIROC Trading Halt - CXR

    IIROC Trading Halt - CXR

  • PR Newswire

    Concordia International Corp. Provides Update On Its Recently Completed Recapitalization Transaction

    Concordia currently has 48,913,504 limited voting shares issued and outstanding, which will commence trading on the Toronto Stock Exchange today, September 11, 2018, under the symbols CXR (in Canadian dollars) and CXR.U (in US dollars).

  • PR Newswire

    Concordia International Corp. Completes Recapitalization Transaction

    MISSISSAUGA, ON, Sept. 6, 2018 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (CXR.TO), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced the completion of the recapitalization transaction (the "Recapitalization Transaction") described in the Company's management information circular dated May 15, 2018 (the "Circular"), and implemented pursuant to the court-approved plan of arrangement dated June 26, 2018, under the Canada Business Corporations Act (the "CBCA Plan"). "We believe that the successful closing of the Recapitalization Transaction will allow us to pursue our strategy and achieve our goals," said Graeme Duncan, Chief Executive Officer of Concordia.